Pulmonary alveolar proteinosis in children
- Timothy J Vece, MD
Timothy J Vece, MD
- Assistant Professor of Pediatrics, Pulmonary Medicine section
- Baylor College of Medicine
Pulmonary alveolar proteinosis (PAP) was first described in 1958 as an uncommon disorder in adults characterized by the accumulation of lipoproteinaceous material within alveoli . The prognosis was highly variable, and for over three decades the pathophysiology and treatment of this disease remained a mystery. With recent developments in molecular genetics, our understanding of the pathogenesis of PAP has improved significantly. At the same time, there were case reports of atypical forms of PAP arising in infants and children. Today there is mounting evidence that most cases of pediatric PAP result from a genetic or acquired defect in surfactant metabolism, leading to excessive accumulation of this material in air spaces .
The pathogenesis, clinical features, and treatment of pulmonary alveolar proteinosis in infants and children are discussed in this topic review. PAP in adults has different causes and clinical manifestations, and is discussed in separate topic reviews. (See "Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults" and "Diagnosis and treatment of pulmonary alveolar proteinosis in adults".)
ETIOLOGY AND PATHOGENESIS
Four forms of pulmonary alveolar proteinosis (PAP) are recognized in children: congenital, acquired, secondary, and idiopathic.
Congenital form — The congenital form of PAP, also known as congenital alveolar proteinosis (CAP), includes inborn errors of surfactant metabolism, lysinuric protein intolerance, and mutations in the components of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor.
It is now recognized that the histopathologic manifestations of the congenital form are different from the autoimmune (classic) form of PAP. (See 'Histopathology' below.)
- ROSEN SH, CASTLEMAN B, LIEBOW AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258:1123.
- Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant proteins. Neonatology 2007; 91:311.
- Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993; 328:406.
- Thouvenin G, Abou Taam R, Flamein F, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95:449.
- Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573.
- Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004; 350:1296.
- Doan ML, Guillerman RP, Dishop MK, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63:366.
- Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond) 2009; 116:27.
- Carré A, Szinnai G, Castanet M, et al. Five new TTF1/NKX2.1 mutations in brain-lung-thyroid syndrome: rescue by PAX8 synergism in one case. Hum Mol Genet 2009; 18:2266.
- Hamvas A, Deterding RR, Wert SE, et al. Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1. Chest 2013; 144:794.
- Santamaria F, Parenti G, Guidi G, et al. Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods. Am J Respir Crit Care Med 1996; 153:731.
- Santamaria F, Brancaccio G, Parenti G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 2004; 145:268.
- Parenti G, Sebastio G, Strisciuglio P, et al. Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course. J Pediatr 1995; 126:246.
- Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2:211.
- Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100:2211.
- Suzuki T, Maranda B, Sakagami T, et al. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Respir J 2011; 37:201.
- Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205:2711.
- Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205:2703.
- Notarangelo LD, Pessach I. Out of breath: GM-CSFRalpha mutations disrupt surfactant homeostasis. J Exp Med 2008; 205:2693.
- Suzuki T, Sakagami T, Young LR, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med 2010; 182:1292.
- Yamamoto H, Yamaguchi E, Agata H, et al. A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis. Pediatr Pulmonol 2008; 43:828.
- Robinson TE, Trapnell BC, Goris ML, et al. Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Chest 2009; 135:842.
- Price A, Manson D, Cutz E, Dell S. Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF. Pediatr Pulmonol 2006; 41:367.
- Latzin P, Tredano M, Wüst Y, et al. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60:39.
- Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest 1997; 111:460.
- Mahut B, Delacourt C, Scheinmann P, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics 1996; 97:117.
- Mazyck EM, Bonner JT, Herd HM, Symbas PN. Pulmonary lavage for childhood pulmonary alveolar proteinosis. J Pediatr 1972; 80:839.
- Mahut B, de Blic J, Le Bourgeois M, et al. Partial and massive lung lavages in an infant with severe pulmonary alveolar proteinosis. Pediatr Pulmonol 1992; 13:50.
- Kurland G, Deterding RR, Hagood JS, et al. An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med 2013; 188:376.
- Berteloot L, Taam RA, Emond-Gonsard S, et al. Primary pulmonary alveolar proteinosis: computed tomography features at diagnosis. Pediatr Radiol 2014; 44:795.
- Gower WA, Wert SE, Ginsberg JS, et al. Fatal familial lung disease caused by ABCA3 deficiency without identified ABCA3 mutations. J Pediatr 2010; 157:62.
- Hamvas A, Cole FS, deMello DE, et al. Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr 1994; 125:356.
- Palomar LM, Nogee LM, Sweet SC, et al. Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. J Pediatr 2006; 149:548.
- Rosen DM, Waltz DA. Hydroxychloroquine and surfactant protein C deficiency. N Engl J Med 2005; 352:207.
- Hiratzka LF, Swan DM, Rose EF, Ahrens RC. Bilateral simultaneous lung lavage utilizing membrane oxygenator for pulmonary alveolar proteinosis in an 8-month-old infant. Ann Thorac Surg 1983; 35:313.
- Seard C, Wasserman K, Benfield JR, et al. Simultaneous bilateral lung lavage (alveolar washing) using partial cardiopulmonary bypass. Am Rev Respir Dis 1970; 101:877.
- Spock A. Long-term survival of paediatric patients with pulmonary alveolar proteinosis treated with lung lavage. Eur Respir J 2005; 25:1127.
- Chibbar R, Shih F, Baga M, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. Mod Pathol 2004; 17:973.
- Markart P, Ruppert C, Wygrecka M, et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J 2007; 29:134.
- Paul K, Müller KM, Oppermann HC, Nützenadel W. Pulmonary alveolar lipoproteinosis in a seven-year-old girl. A follow-up over six years. Acta Paediatr Scand 1991; 80:477.
- ETIOLOGY AND PATHOGENESIS
- Congenital form
- - Inborn errors of surfactant metabolism
- - Lysinuric protein intolerance
- - GM-CSF receptor
- Acquired form
- Secondary form
- Idiopathic form
- CLINICAL FEATURES
- Signs and symptoms
- Pulmonary function tests
- Laboratory tests
- Lung biopsy
- Infants and older children
- - Anti-inflammatory therapy
- - Whole lung lavage
- - Recombinant GM-CSF
- SUMMARY AND RECOMMENDATIONS